A Phase III, 52-Week, Open-Label Study to Evaluate the Safety and Efficacy of 5% Sofpironium Bromide (BBI-4000) Gel in Japanese Patients with Primary Axillary Hyperhidrosis.

Tomoko Fujimoto,Yoichiro Abe,Masaru Igarashi,Akiko Ishikoh,Tokuya Omi,Hiroki Kanda,Hiroto Kitahara,Miwako Kinoshita,Ichiro Nakasu,Naoko Hattori,Yuki Horiuchi,Ryuji Maruyama,Haruko Mizutani,Yoshiyuki Murakami,Chiharu Watanabe,Akihiro Kume,Takaaki Hanafusa,Masamitsu Hamaguchi,Akira Yoshioka,Yuriko Egami,Keizo Matsuo,Tomoko Matsuda,Motoki Akamatsu,Toshiyuki Yorozuya,Shinichi Takayama,Hiroo Yokozeki

Journal of dermatology（2021）

引用 8|浏览8
暂无评分
关键词
52&#8208,week study,BBI&#8208,4000,phase III study,primary axillary hyperhidrosis,sofpironium bromide gel
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要